At variance with vitamin K antagonists, the new oral anticoagulants (NOAs) can be prescribed at fixed dosage without adjustment by laboratory testing. However, this does not necessarily mean that the laboratory does not play a role for their management. This position paper represents the consensus document of three Italian scientific societies dealing with laboratory issues in thrombosis and hemostasis. It is aimed at reviewing: 1) which test(s) should be used to evaluate the anticoagulant effect of each of the NOAs presently available (i.e., dabigatran, rivaroxaban and apixaban); 2) the patients to be investigated; and 3) the timing of investigation. Copyright
Position Paper on Laboratory Testing for Patients Taking New Oral Anticoagulants. Consensus Document of FCSA, SIMeL, SIBioC and CISMEL / A. Tripodi, G. Di Iorio, G. Lippi, S. Testa, C. Manotti. - In: CLINICAL CHEMISTRY AND LABORATORY MEDICINE. - ISSN 1434-6621. - 50:12(2012), pp. 2137-2140.
Position Paper on Laboratory Testing for Patients Taking New Oral Anticoagulants. Consensus Document of FCSA, SIMeL, SIBioC and CISMEL
A. TripodiPrimo
;
2012
Abstract
At variance with vitamin K antagonists, the new oral anticoagulants (NOAs) can be prescribed at fixed dosage without adjustment by laboratory testing. However, this does not necessarily mean that the laboratory does not play a role for their management. This position paper represents the consensus document of three Italian scientific societies dealing with laboratory issues in thrombosis and hemostasis. It is aimed at reviewing: 1) which test(s) should be used to evaluate the anticoagulant effect of each of the NOAs presently available (i.e., dabigatran, rivaroxaban and apixaban); 2) the patients to be investigated; and 3) the timing of investigation. CopyrightPubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.